Literature DB >> 1808608

The pharmacokinetics of antipyrine and three of its metabolites in the rabbit: intravenous administration of pure metabolites.

J V St Peter1, Y Abul-Hajj, W M Awni.   

Abstract

Antipyrine (AP) is a commonly used probe of oxidative metabolism. Indirect evidence demonstrates formation rate limited disposition of its metabolites. Kinetic studies using antipyrine and its major metabolites 3-hydroxymethylantipyrine (HMA), norantipyrine (NORA), and 4-hydroxyantipyrine (OHA) were completed to investigate the metabolic fate of preformed antipyrine metabolite and to demonstrate directly formation rate-limited metabolite disposition in vivo. Bolus injections of antipyrine and preformed metabolites (40-50 mg/kg) were administered to male, New Zealand white rabbits. Plasma and urine were analyzed using HPLC. These studies demonstrate that HMA, NORA, and OHA are formation rate limited in the rabbit. NORA appears to undergo further extensive oxidative and conjugative metabolism. Unknown additional peaks were detected in urine after NORA dosing but not after HMA or OHA administration. Mass spectroscopy of the unknown HPLC eluents identified potential structures of these NORA metabolites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1808608     DOI: 10.1023/a:1015830013451

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

1.  Disposition of antipyrine and acetaminophen given alone and in combination to human subjects.

Authors:  W M Awni; J V St Peter; J M Kovarik; G R Matzke
Journal:  Pharm Res       Date:  1990-02       Impact factor: 4.200

2.  Modified high-performance liquid chromatographic assay for antipyrine and its three major metabolites in urine.

Authors:  J V St Peter; W M Awni
Journal:  J Chromatogr       Date:  1989-09-29

3.  Quinidine does not alter antipyrine metabolism.

Authors:  S K Bowles; L Cardozo; D J Edwards
Journal:  J Clin Pharmacol       Date:  1990-03       Impact factor: 3.126

4.  An improved synthesis of 3-hydroxymethylantipyrine using antipyrine as starting material.

Authors:  W Buijs; B van Meeteren-Wälchli; D D Breimer; A van der Gen
Journal:  Arzneimittelforschung       Date:  1986-03

5.  Differential effects of enzyme induction on antipyrine metabolite formation.

Authors:  M Danhof; R M Verbeek; C J van Boxtel; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

6.  Influence of cimetidine on steady state concentration and metabolite formation from antipyrine infused with a rectal osmotic mini pump.

Authors:  M W Teunissen; C H Kleinbloesem; L G de Leede; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Human metabolism of antipyrine labelled with 14C in the pyrazolone ring or in the N-methyl group.

Authors:  H Uchino; T Inaba; W Kalow
Journal:  Xenobiotica       Date:  1983-03       Impact factor: 1.908

8.  Pharmacokinetics of drugs in rabbits with experimental acute renal failure.

Authors:  A Van Peer; F Belpaire; M Bogaert
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547

9.  Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.

Authors:  M W Teunissen; P Spoelstra; C W Koch; B Weeda; W van Duyn; A R Janssens; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

10.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

View more
  1 in total

1.  1,5-Dimethyl-2-phenyl-1H-pyrazol-3(2H)-one-4,4'-(propane-2,2-di-yl)bis-[1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one] (1/1).

Authors:  Krzysztof Lyczko
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-12-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.